Based on the provided trial data, this appears to be an observational imaging study using PET scanning technology to examine tau and amyloid proteins in the brain. No medications are being tested in this trial. The study focuses on:

Tau PET tracers – These are specialized radioactive substances injected into the bloodstream before a PET scan. They bind to tau protein deposits in the brain, allowing researchers to see their location and amount. These tracers are diagnostic tools, not treatments.

Amyloid PET tracers – Similar to tau tracers, these are diagnostic substances that bind to amyloid protein deposits in the brain, making them visible during PET scanning. These are also used for imaging purposes only and are not therapeutic agents.

Alzheimer’s Disease – A progressive brain disorder that gradually destroys memory, thinking skills, and the ability to carry out simple tasks. It begins with mild changes in memory and thinking abilities, often years before noticeable symptoms appear. The disease causes brain cells to degenerate and die, leading to a continuous decline in memory and cognitive function. Physical changes in the brain include abnormal buildup of proteins called amyloid plaques and tau tangles. These changes initially affect parts of the brain controlling memory, but eventually spread to areas involved in language, reasoning, and social behavior. The disease typically progresses from mild forgetfulness to severe impairment of mental and physical functions.